Table 3.
Skin permeability parameters of DCN after topical application of E1, DCN-loaded bilosomes, and drug suspension (A) and pharmacokinetic parameters of E1 in comparison with DCN oral suspension (B).
(A) | Treatment | ||
Skin permeability parameters | E1 | DCN-loaded bilosomes | Drug suspension |
Total amount of drug permeated per unit area in 24 h (µg/cm2)a | 1150.92 ± 194.71 | 1003.50 ± 47.38 | 59.44 ± 0.50 |
Jmax (µg/cm2/h)a | 27.24 ± 4.61 | 23.75 ± 1.12 | 1.41 ± 0.01 |
ER | 19.36 | 16.84 | 1 |
(B) | |||
In-vivo pharmacokinetic parameters | E1 | DCN oral suspension | |
Cmax (µg/mL)b | 0.76 ± 0.04 | 2.24 ± 1.12 | |
Tmax (h)c | 1 | 1 | |
AUC0→24 (µg h/mL)b | 9.26 ± 3.02 | 9.95 ± 1.04 | |
AUC0→∞ (µg h/mL)b | 20.65 ± 16.40 | 15.49 ± 10.04 |
Jmax: flux; ER: enhancement ratio.
Data presented as mean ± SD (n = 3).
Data presented as mean ± SD (n = 6).
Data presented as median.